PTPN11 and neoplasm: On average, Osimertinib reduced 55.96 % of the tumor weight of SHP2 over-expressing tumors from 1.612 to 0.710 g in control, and 89.51 % of the tumor weight from 1.316 to 0.138 g in SHP2 knock-down tumors (Fig. 2E).